Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8054)
All Articles published online
|
Publishing Process of This Article
|
Nov 15, 2018 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 [PMID: 30487953 DOI: 10.4251/wjgo.v10.i11.421] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v10/i11/421.htm |
| Number | Citing Articles |
| 1 |
Chaobin He, Jun Wang, Yu Zhang, Xiaojun Lin, Shengping Li. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. Pancreatology 2020; 20(3): 477 doi: 10.1016/j.pan.2020.02.009
|
| 2 |
Jayanth Surya Narayanan Shankara Narayanan, Katie Frizzi, Suna Erdem, Partha Ray, David Jaroch, Bryan Cox, Steven Katz, Diego Vicente, Rebekah White. Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Discover Oncology 2022; 13(1) doi: 10.1007/s12672-022-00483-4
|
| 3 |
Beilei Zhang, Fengyan Zhou, Jiaze Hong, Derry Minyao Ng, Tong Yang, Xinyu Zhou, Jieyin Jin, Feifei Zhou, Ping Chen, Yunbao Xu. The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02291-6
|
| 4 |
Chaobin He, Jun Wang, Shuxin Sun, Yu Zhang, Shengping Li. Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. Journal of Oncology 2019; 2019: 1 doi: 10.1155/2019/9346017
|
| 5 |
Jonathan D. Mizrahi, Jane E. Rogers, Kenneth R. Hess, Robert A. Wolff, Gauri R. Varadhachary, Milind M. Javle, Rachna T. Shroff, Linus Ho, David R. Fogelman, Kanwal P.S. Raghav, Michael J. Overman, Shubham Pant. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 2020; 20(3): 501 doi: 10.1016/j.pan.2020.01.005
|
| 6 |
Anna Silvia Wenning, Christoph O. Ryser, Andreas Andreou, Beat Gloor, Martin D. Berger. Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont?. Schweizer Gastroenterologie 2021; 2(4): 138 doi: 10.1007/s43472-021-00054-y
|
| 7 |
Jiayuan Chen, Qingling Hua, Haihong Wang, Dejun Zhang, Lei Zhao, Dandan Yu, Guoliang Pi, Tao Zhang, Zhenyu Lin. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08605-x
|
| 8 |
Shiao Li Oei, Friedemann Schad. Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?. Cancers 2023; 15(4): 1116 doi: 10.3390/cancers15041116
|
| 9 |
Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu. Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX. Journal of Korean Society of Health-System Pharmacists 2024; 41(3): 253 doi: 10.32429/jkshp.2024.41.3.003
|
| 10 |
Chaobin He, Shuxin Sun, Yu Zhang, Shengping Li. Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irreversible Electroporation. Journal of Inflammation Research 2021; : 1689 doi: 10.2147/JIR.S307884
|
| 11 |
Aurélien Lambert, Thierry Conroy, Michel Ducreux. Future directions in drug development in pancreatic cancer. Seminars in Oncology 2021; 48(1): 47 doi: 10.1053/j.seminoncol.2021.02.002
|
| 12 |
Jiyoung Keum, Hee Seung Lee, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers 2022; 14(5): 1244 doi: 10.3390/cancers14051244
|
| 13 |
M. Sinn, V. Heinemann. Systemtherapie des metastasierten Pankreaskarzinoms: Aktuelle Standards und Perspektiven. Der Onkologe 2019; 25(8): 696 doi: 10.1007/s00761-019-0569-2
|
| 14 |
Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers 2023; 15(2): 416 doi: 10.3390/cancers15020416
|
| 15 |
Hortense Chevalier, Angélique Vienot, Astrid Lièvre, Julien Edeline, Farid El Hajbi, Charlotte Peugniez, Dewi Vernerey, Aurélia Meurisse, Pascal Hammel, Cindy Neuzillet, Christophe Borg, Anthony Turpin. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. The Oncologist 2020; 25(11): e1701 doi: 10.1634/theoncologist.2020-0577
|
| 16 |
Ayhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, Gabriella Pittau, Mazen Haydar, Pamela Biondani, Yusuf Gumus, Amale Chebib, Wathek Almohamad, Pasquale F. Innominato. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07004-y
|
| 17 |
Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, Akio Ido, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Tsuyoshi Shirakawa, Taiga Otsuka. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer. Pancreas 2021; 50(7): 957 doi: 10.1097/MPA.0000000000001859
|
| 18 |
L. I. Moskvicheva, L. V. Bolotina. Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. Research and Practical Medicine Journal 2020; 7(4): 118 doi: 10.17709/2409-2231-2020-7-4-10
|
| 19 |
Marko Damm, Ljupcho Efremov, Benedikt Birnbach, Gretel Terrero, Jörg Kleeff, Rafael Mikolajczyk, Jonas Rosendahl, Patrick Michl, Sebastian Krug. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers 2021; 13(17): 4326 doi: 10.3390/cancers13174326
|
| 20 |
L.I. Moskvicheva, A.L. Kornietskaya, L.V. Bolotina. Safety and efficiency of combination treatment including high-intensity focused ultrasound therapy in patients with pancreatic cancer. Onkologiya. Zhurnal imeni P.A.Gertsena 2022; 11(5): 11 doi: 10.17116/onkolog20221105111
|
| 21 |
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Emmanuel Mitry, Philippe Alexandre Cassier, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu Batlle, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Teresa Macarulla. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. The Lancet Oncology 2024; 25(7): 853 doi: 10.1016/S1470-2045(24)00263-8
|
| 22 |
Aurélien Lambert, Lilian Schwarz, Ivan Borbath, Aline Henry, Jean-Luc Van Laethem, David Malka, Michel Ducreux, Thierry Conroy. An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919875568
|
| 23 |
Manish Manrai, T V S V G K Tilak, Saurabh Dawra, Sharad Srivastava, Anupam Singh. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World Journal of Gastroenterology 2021; 27(39): 6572-6589 doi: 10.3748/wjg.v27.i39.6572
|
| 24 |
Xiaorong Ye, Yue Yu, Xiaohu Zheng, Hongdi Ma. Clinical immunotherapy in pancreatic cancer. Cancer Immunology, Immunotherapy 2024; 73(4) doi: 10.1007/s00262-024-03632-6
|
| 25 |
Dilmurodjon Eshmuminov, Botirjon Aminjonov, Russell F. Palm, Giuseppe Malleo, Ryan K. Schmocker, Raëf Abdallah, Changhoon Yoo, Walid L. Shaib, Marcel André Schneider, Elena Rangelova, Yoo Jin Choi, Hongbeom Kim, J. Bart Rose, Sameer Patel, Gregory C. Wilson, Sarah Maloney, Lea Timmermann, Klaus Sahora, Fabian Rössler, Víctor Lopez-Lopez, Emanuel Boyer, Laura Maggino, Thomas Malinka, Jeong Youp Park, Matthew H. G. Katz, Laura Prakash, Syed A. Ahmad, Scott Helton, Jin-Young Jang, Sarah E. Hoffe, Roberto Salvia, Julien Taieb, Jin He, Pierre-Alain Clavien, Ulrike Held, Kuno Lehmann. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Annals of Surgical Oncology 2023; 30(7): 4417 doi: 10.1245/s10434-023-13353-2
|
| 26 |
Kwangrok Jung, Suhyun Choi, Hyunjoo Song, Kyuhan Kwak, Soyeon Anh, Jae Hyup Jung, Bomi Kim, Jinwoo Ahn, Jaihwan Kim, Jin-Hyeok Hwang, Jong-chan Lee. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231175441
|
| 27 |
Ghazaleh Pourali, Ghazaleh Donyadideh, Shima Mehrabadi, Fiuji Hamid, Seyed Mahdi Hassanian, Gordon A. Ferns, Majid Khazaei, Amir Avan. Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. 2024; : 345 doi: 10.1016/B978-0-443-19142-8.00008-5
|